BIRC2 and breast carcinoma: As EVO has been reported to inhibit the expression of IAPs, such as XIAP, survivin and cIAP1 [19], and to modulate ERK signaling [21]–[23], we hypothesized that EVO could reverse DOX-resistant breast cancer cells by inhibiting the Ras/MEK/ERK pathway and IAPs.